In 2017, deal volume in the biopharma space slowed for the third consecutive year. Value in all of the pharma and life sciences sector totaled only about $181 billion, down 23% from a year earlier, according to PricewaterhouseCoopers.

But according to Intec Pharma Ltd. (NTEC) Chief Executive Officer and Vice Chairman Jeffrey Meckler, a slowdown one year doesn't necessarily portend a slowdown the next year. Rather, innovation is often what drives mergers and acquisitions in biopharma.

"Where there's real innovation, there's always someone willing to pay for it," Meckler said.

More from Mergers and Acquisitions

These 3 Marijuana-Related Stocks Are Ripe for Takeover

These 3 Marijuana-Related Stocks Are Ripe for Takeover

Tech M&A Actions Shows No Signs of Abating

Tech M&A Actions Shows No Signs of Abating

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

IBM Sells Software Portfolio to India's HCL Technologies

IBM Sells Software Portfolio to India's HCL Technologies

Euromoney Buys The Deal, BoardEx

Euromoney Buys The Deal, BoardEx